文献速递神经肿瘤

HDAC3表达与胶质瘤患者预后及分级相关:基于转录组和临床证据的多样化分析

HDAC3 Expression Correlates with the Prognosis and Grade of Patients with Glioma: A Diversification Analysis Based on Transcriptome and Clinical Evidence.
PubMed 文献 · World Neurosurg · 2018-07-24

本研究通过细胞系定量PCR、Oncomine数据库分析、中国胶质瘤基因组图谱325例预后分析及纳入490例患者的meta分析,探讨HDAC3表达与胶质瘤预后和分级的关系。结果显示胶质瘤中HDAC3 RNA表达高于正常胶质细胞系,低HDAC3表达者总生存和无进展生存均更优,WHO III级和IV级mRNA水平显著高于II级,HDAC3可能作为区分胶质瘤分级的生物标志物。

要点

  • 胶质瘤细胞系中HDAC3 RNA过表达(P < 0.05)。
  • 低HDAC3表达者总生存和无进展生存均显著优于高表达者。
  • WHO III级和IV级HDAC3 mRNA水平显著高于II级(P < 0.05)。

核心结论

  • HDAC3 mRNA在胶质瘤中的表达高于正常胶质细胞系。
  • 低HDAC3 mRNA表达水平预示更好的总生存。
  • HDAC3表达可能作为区分胶质瘤分级的生物标志物。

研究设计与样本

  • 研究采用定量实时聚合酶链反应检测胶质瘤和正常胶质细胞系中HDAC3表达。
  • 进行Oncomine数据库分析和预后分析。
  • 采用Spearman秩相关检验分析世界卫生组织(WHO)分级与HDAC3的相关性。
  • 进行meta分析以确认结论。
  • 预后分析纳入来自中国胶质瘤基因组图谱的325例胶质瘤样本。

主要发现

  • 胶质瘤细胞系中检测到HDAC3 RNA过表达(P < 0.05)。
  • 从Oncomine数据库筛选的4个数据集显示胶质瘤中HDAC3表达水平持续高于正常组织(P < 0.001)。
  • 325例胶质瘤样本分析显示,低HDAC3表达患者较高HDAC3表达患者总生存显著更好(HR 1.992;95%CI 1.490-2.662;P < 0.0001)。
  • 低HDAC3表达患者较高HDAC3表达患者无进展生存显著更好(HR 1.874;95%CI 1.412-2.487;P < 0.0001)。
  • WHO III级组和WHO IV级组的信使RNA(mRNA)水平均显著高于WHO II级组(P < 0.05)。

关键数值与推荐

  • meta分析亚组分析汇总数据显示,低HDAC3 mRNA水平者总生存显著更长(HR 3.38;95%CI 1.80-6.37;P = 0.0002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to clarify the relationship between histone deacetylase 3 (HDAC3) expression and the prognosis as well as the grade of patients with glioma. METHODS: The quantitative real-time polymerase chain reaction was profiled to examine the HDAC3 expression in glioma and normal glial cell lines. An Oncomine database analysis and prognosis analysis were performed. The correlation between World Health Organization (WHO) grade and HDAC3 was analyzed by Spearman rank correlation test. A meta-analysis was performed to confirm the conclusion. RESULTS: HDAC3 RNA overexpression in glioma cell lines was detected (P < 0.05). Four data sets were screened from the Oncomine database and showed that the expression level of HDAC3 was consistently higher in glioma than in normal tissue (P < 0.001). The prognostic analysis of 325 glioma samples from the Chinese Glioma Genome Atlas showed that patients with low HDAC3 expression had significantly better overall survival (OS) and progression-free survival (PFS) than did patients with high HDAC3 expression [hazard ratio [HR], 1.992; 95% confidence interval [CI], 1.490-2.662; P < 0.0001 and HR, 1.874; 95% CI, 1.412-2.487; P < 0.0001, respectively]. Both the WHO grade III group and the WHO grade IV group expressed significantly higher messenger RNA (mRNA) level than did the WHO grade II group (P < 0.05). Four cohort studies consisting of 490 patients were included in the meta-analysis. The pooled data of subgroup analysis showed significantly longer OS in low HDAC3 mRNA level [HR, 3.38; 95% CI, 1.80-6.37; P = 0.0002]. CONCLUSIONS: HDAC3 mRNA was expressed more in glioma than in the normal glial cell line. Low HDAC3 mRNA expression levels predicted better OS. HDAC3 expression could be a biomarker to discriminate glioma grade.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Zhong S, Fan Y, Wu B, et al. HDAC3 Expression Correlates with the Prognosis and Grade of Patients with Glioma: A Diversification Analysis Based on Transcriptome and Clinical Evidence. World Neurosurg. 2018. PMID: 30053564. doi:10.1016/j.wneu.2018.07.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。